Improved understanding around the pathophysiology and heterogeneity of acute myeloid leukemia (AML) has led to a rapidly evolving treatment paradigm for this disease. New therapies and drug approvals have improved outcomes for patients, and in those not eligible for standard induction chemotherapy followed by transplantation, lower-intensity therapies have allowed patients to achieve disease control.

Due to the COVID-19 pandemic, the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition (ASH 2020) was held virtually – and it didn’t disappoint in the quality and breadth of data presented.

In this roundtable discussion, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, and Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA, discuss and debate the key updates in the management of patients with AML presented at ASH 2020.

The post The AML Sessions: highlights from ASH 2020 appeared first on VJHemOnc.